Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells

Blood

Volumn 113, Issue 5, 2009, Pages 1167-1174

  Tolar, Jakub ^a   Akemi, Ishida Yamamoto ^b   Riddle, Megan ^a   McElmurry, Ron T ^a   Osborn, Mark ^a   Xia, Lily ^a   Lund, Troy ^a   Slattery, Catherine ^a   Uitto, Jouni ^c   Christiano, Angela M ^d   Wagner, John E ^a   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL HOMING; CELL POPULATION; COLLAGEN TYPE 7 GENE; CONTROLLED STUDY; EPIDERMOLYSIS BULLOSA; FEMALE; FIBER; GENE; LETHALITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN FRAGILITY; ANIMAL; DISEASE MODEL; EPIDERMOLYSIS BULLOSA DYSTROPHICA; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; MUTATION; PATHOLOGY;

ANIMALS; BASEMENT MEMBRANE; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; COLLAGEN TYPE VII; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA DYSTROPHICA; HUMANS; MICE; MICE, KNOCKOUT; MUTATION;

EID: 60849091919     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-161299     Document Type: Article

References (44)

1. Pulkkinen L, Uitto J. Mutation analysis and molecular genetics of epidermolysis bullosa. Matrix Biol. 1999;18:29-42.
2. Uitto J, Christiano AM. Molecular genetics of the cutaneous basement membrane zone: perspectives on epidermolysis bullosa and other blistering skin diseases. J Clin Invest. 1992;90:687-692.
3. Burgeson RE. Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol. 1993;101:252-255.
4. Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58:931-950.
5. Chen M, Kasahara N, Keene DR, et al. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet. 2002;32:670-675.
6. Ortiz-Urda S, Thyagarajan B, Keene DR, et al. Stable nonviral genetic correction of inherited human skin disease. Nat Med. 2002;8:1166-1170.
7. Woodley DT, Keene DR, Atha T, et al. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther. 2004;10:318-326.
8. Mecklenbeck S, Compton SH, Mejia JE, et al. A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line. Hum Gene Ther. 2002;13:1655-1662.
9. Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006;12:1397-1402.
10. Baldeschi C, Gache Y, Rattenholl A, et al. Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum Mol Genet. 2003;12:1897-1905.
11. Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest. 2003;111:251-255.
12. Gache Y, Baldeschi C, Del Rio M, et al. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther. 2004;15:921-933.
13. Woodley DT, Keene DR, Atha T, et al. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med. 2004;10:693-695.
14. Bickenbach JR. Isolation, characterization, and culture of epithelial stem cells. Methods Mol Biol. 2005;289:97-102.
15. Tögel F, Westenfelder C. Adult bone marrowderived stem cells for organ regeneration and repair. Dev Dyn. 2007;236:3321-3331.
16. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood. 2004; 103:1662-1668.
17. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41-49.
18. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair: current views. Stem Cells. 2007;25:2896-2902.
19. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A. 2007;104:11002-11007.
20. Kunter U, Rong S, Djuric Z, et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol. 2006;17:2202-2212.
21. Phinney DG, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des. 2005;11:1255-1265.
22. Tolar J, Wang X, Braunlin E, et al. The host immune response is essential for the beneficial effect of adult stem cells after myocardial ischemia. Exp Hematol. 2007;35:682-690.
23. Pǎunescu V, Deak E, Herman D, et al. In vitro differentiation of human mesenchymal stem cells to epithelial lineage. J Cell Mol Med. 2007;11: 502-508.
24. Van Arnam JS, Herzog E, Grove J, et al. Engraftment of bone marrow-derived epithelial cells. Stem Cell Rev. 2005;1:21-27.
25. Murata H, Janin A, Leboeuf C, et al. Donorderived cells and human graft-versus-host disease of the skin. Blood. 2007;109:2663-2665.
26. Badiavas EV, Abedi M, Butmarc J, Falanga V, Quesenberry P. Participation of bone marrow derived cells in cutaneous wound healing. J Cell Physiol. 2003;196:245-250.
27. Fathke C, Wilson L, Hutter J, et al. Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells. 2004;22: 812-822.
28. Heinonen S, Mannikko M, Klement JF, Whitaker-Menezes D, Murphy GF, Uitto J. Targeted inactivation of the type VII collagen gene (Co17a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J Cell Sci. 1999;112(pt 21):3641-3648.
29. Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol. 2002; 30:896-904.
30. Taylor PA, McElmurry RT, Lees CJ, Harrison DE, Blazar BR. Allogenic fetal liver cells have a distinct competitive engraftment advantage over adult bone marrow cells when infused into fetal as compared with adult severe combined immunodeficient recipients. Blood. 2002;99:1870-1872.
31. Yilmaz OH, Kiel MJ, Morrison SJ. SLAM family markers are conserved among hematopoietic stem cells from old and reconstituted mice and markedly increase their purity. Blood. 2006;107: 924-930.
32. Krause DS, Theise ND, Collector MI, et al. Multiorgan, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369-377.
33. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109-1121.
34. Orchard PJ, Blazar BR, Wagner J, Charnas L, Krivit W, Tolar J. Hematopoietic cell therapy for metabolic disease. J Pediatr. 2007;151:340-346.
35. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol. 2008;8:290-301.
36. Kiel MJ, Yilmaz OH, Morrison SJ. CD150-cells are transiently reconstituting multipotent progenitors with little or no stem cell activity. Blood. 2008; 111:4413-4414; author reply: 4414-4415.
37. Weksberg DC, Chambers SM, Boles NC, Goodell MA. CD150-side population cells represent a functionally distinct population of long-term hematopoietic stem cells. Blood. 2008;111:2444-2451.
38. Woodley DT, Remington J, Huang Y, et al. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther. 2007;15:628-635.
39. Porteus MH, Connelly JP, Pruett SM. A look to future directions in gene therapy research for monogenic diseases. PLoS Genet. 2006;2:e133.
40. Remington J, Chen M, Burnett J, Woodley DT. Autoimmunity to type VII collagen: epidermolysis bullosa acquisita. Curr Dir Autoimmun. 2008;10: 195-205.
41. Fritsch A, Loeckermann S, Kern JS, et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest. 2008;118:1669-1679.
42. Ferrari S, Pellegrini G, Matsui T, Mavilio F, De Luca M. Gene therapy in combination with tissue engineering to treat epidermolysis bullosa. Expert Opin Biol Ther. 2006;6:367-378.
43. Fine JD. Epidermolysis bullosa: a genetic disease of altered cell adhesion and wound healing, and the possible clinical utility of topically applied thymosin beta4. Ann N Y Acad Sci. 2007;1112:396-406.
44. Fivenson DP, Scherschun L, Choucair M, Kukuruga D, Young J, Shwayder T. Graftskin therapy in epidermolysis bullosa. J Am Acad Dermatol. 2003;48:886-892.